Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 546

1.

CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.

Liu T, Yan Z, Liu Y, Choy E, Hornicek FJ, Mankin H, Duan Z.

Cell Physiol Biochem. 2018;46(3):1218-1230. doi: 10.1159/000489072. Epub 2018 Apr 16.

2.

CDK4 expression in chordoma: A potential therapeutic target.

Liu T, Shen JK, Choy E, Zhang Y, Mankin HJ, Hornicek FJ, Duan Z.

J Orthop Res. 2018 Jun;36(6):1581-1589. doi: 10.1002/jor.23819. Epub 2017 Dec 22.

PMID:
29194728
3.

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.

Liao Y, Chen L, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

Oncotarget. 2017 May 2;8(18):30276-30287. doi: 10.18632/oncotarget.16326.

4.

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.

Liao Y, Sassi S, Halvorsen S, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

Sci Rep. 2017 Mar 6;7:43941. doi: 10.1038/srep43941.

5.

Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.

Gao Y, Shen J, Choy E, Mankin H, Hornicek F, Duan Z.

Cell Oncol (Dordr). 2017 Jun;40(3):209-218. doi: 10.1007/s13402-017-0316-x. Epub 2017 Feb 27.

PMID:
28243976
6.

miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo.

Duan Z, Gao Y, Shen J, Choy E, Cote G, Harmon D, Bernstein K, Lozano-Calderon S, Mankin H, Hornicek FJ.

Mol Oncol. 2017 Feb;11(2):151-166. doi: 10.1002/1878-0261.12015. Epub 2016 Oct 24.

7.

Functional and oncological outcome after surgical resection of the scapula and clavicle for primary chondrosarcoma.

Nota SP, Russchen MJ, Raskin KA, Mankin HJ, Hornicek FJ, Schwab JH.

Musculoskelet Surg. 2017 Apr;101(1):67-73. doi: 10.1007/s12306-016-0437-9. Epub 2016 Nov 29.

PMID:
27900545
8.

Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.

Liu X, Gao Y, Shen J, Yang W, Choy E, Mankin H, Hornicek FJ, Duan Z.

Mol Cancer Ther. 2016 Jul;15(7):1691-701. doi: 10.1158/1535-7163.MCT-16-0032. Epub 2016 May 20.

9.

Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats.

Gao Y, Shen JK, Choy E, Zhang Z, Mankin HJ, Hornicek FJ, Duan Z.

Sci Rep. 2016 May 9;6:25659. doi: 10.1038/srep25659.

10.

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro.

Shen JK, Cote GM, Gao Y, Choy E, Mankin HJ, Hornicek FJ, Duan Z.

Sci Rep. 2016 Apr 29;6:25239. doi: 10.1038/srep25239.

11.

Case series and literature review of skeletal tumors and their incidence in the Gaucher disease population.

Murugesan V, Lischuk A, Haims A, Lackman R, Brooks JS, Mankin H, Mistry PK.

Am J Hematol. 2016 Jul;91(7):736-41. doi: 10.1002/ajh.24398. Epub 2016 May 18. Review. No abstract available.

12.

Colour Terms Affect Detection of Colour and Colour-Associated Objects Suppressed from Visual Awareness.

Forder L, Taylor O, Mankin H, Scott RB, Franklin A.

PLoS One. 2016 Mar 29;11(3):e0152212. doi: 10.1371/journal.pone.0152212. eCollection 2016.

13.

Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray.

Gao Y, Liao Y, Shen JK, Feng Y, Choy E, Cote G, Harmon D, Mankin HJ, Hornicek FJ, Duan Z.

J Orthop Res. 2016 Sep;34(9):1606-12. doi: 10.1002/jor.23173. Epub 2016 Feb 2.

14.

p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.

Ye S, Shen J, Choy E, Yang C, Mankin H, Hornicek F, Duan Z.

Cancer Chemother Pharmacol. 2016 Feb;77(2):349-56. doi: 10.1007/s00280-015-2944-z. Epub 2015 Dec 23.

15.

Clinical and biological significance of PIM1 kinase in osteosarcoma.

Liao Y, Feng Y, Shen J, Gao Y, Cote G, Choy E, Harmon D, Mankin H, Hornicek F, Duan Z.

J Orthop Res. 2016 Jul;34(7):1185-94. doi: 10.1002/jor.23134. Epub 2015 Dec 31.

16.

NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.

Ye S, Zhang J, Shen J, Gao Y, Li Y, Choy E, Cote G, Harmon D, Mankin H, Gray NS, Hornicek FJ, Duan Z.

Br J Pharmacol. 2016 Feb;173(3):613-26. doi: 10.1111/bph.13395. Epub 2016 Jan 15.

17.

Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.

Sun X, Guo W, Shen JK, Mankin HJ, Hornicek FJ, Duan Z.

Sarcoma. 2015;2015:232010. doi: 10.1155/2015/232010. Epub 2015 Sep 1. Review.

18.

CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma.

Gao Y, Feng Y, Shen JK, Lin M, Choy E, Cote GM, Harmon DC, Mankin HJ, Hornicek FJ, Duan Z.

Sci Rep. 2015 Jun 16;5:11365. doi: 10.1038/srep11365.

19.

Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells.

Zhang L, Lyer AK, Yang X, Kobayashi E, Guo Y, Mankin H, Hornicek FJ, Amiji MM, Duan Z.

Int J Nanomedicine. 2015 Apr 15;10:2913-24. doi: 10.2147/IJN.S79143. eCollection 2015.

20.

Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.

Yang X, Shen J, Gao Y, Feng Y, Guan Y, Zhang Z, Mankin H, Hornicek FJ, Duan Z.

Int J Cancer. 2015 Oct 15;137(8):2029-39. doi: 10.1002/ijc.29574. Epub 2015 May 5.

21.

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.

Feng Y, Shen J, Gao Y, Liao Y, Cote G, Choy E, Chebib I, Mankin H, Hornicek F, Duan Z.

Oncotarget. 2015 May 10;6(13):11139-49.

22.

MicroRNA-155 expression is independently predictive of outcome in chordoma.

Osaka E, Kelly AD, Spentzos D, Choy E, Yang X, Shen JK, Yang P, Mankin HJ, Hornicek FJ, Duan Z.

Oncotarget. 2015 Apr 20;6(11):9125-39.

23.

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.

Gao Y, Foster R, Yang X, Feng Y, Shen JK, Mankin HJ, Hornicek FJ, Amiji MM, Duan Z.

Oncotarget. 2015 Apr 20;6(11):9313-26.

24.

NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.

Yang X, Feng Y, Gao Y, Shen J, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z.

Gynecol Oncol. 2015 Apr;137(1):134-42. doi: 10.1016/j.ygyno.2015.02.002. Epub 2015 Feb 10.

PMID:
25677062
25.

What's new in primary bone tumors.

Schwab JH, Lozano-Calderon SA, Mankin HJ, Raskin KA, Hornicek FJ.

J Bone Joint Surg Am. 2014 Dec 17;96(24):2099-104. doi: 10.2106/JBJS.N.01014. No abstract available.

PMID:
25520345
26.

Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.

Feng Y, Sassi S, Shen JK, Yang X, Gao Y, Osaka E, Zhang J, Yang S, Yang C, Mankin HJ, Hornicek FJ, Duan Z.

J Orthop Res. 2015 Feb;33(2):199-207. doi: 10.1002/jor.22745. Epub 2014 Oct 27.

27.

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.

Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ.

BMC Cancer. 2014 Sep 19;14:681. doi: 10.1186/1471-2407-14-681.

28.

Liposarcoma: a soft tissue tumor with many presentations.

Mankin HJ, Mankin KP, Harmon DC.

Musculoskelet Surg. 2014 Dec;98(3):171-7. doi: 10.1007/s12306-014-0332-1. Epub 2014 Jul 22. Review.

PMID:
25047632
29.

Schwannoma: a rare benign tumor of soft tissues.

Mankin HJ, Mankin KP.

Musculoskelet Surg. 2014 Aug;98(2):95-9. doi: 10.1007/s12306-014-0333-0. Epub 2014 Jun 24. Review.

PMID:
24958196
30.

Programmed cell death ligand 1 expression in osteosarcoma.

Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z.

Cancer Immunol Res. 2014 Jul;2(7):690-698. doi: 10.1158/2326-6066.CIR-13-0224. Epub 2014 Apr 21.

31.

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.

Yang X, Yang P, Shen J, Osaka E, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z.

Br J Cancer. 2014 Jun 10;110(12):2896-904. doi: 10.1038/bjc.2014.254. Epub 2014 May 22.

32.

MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug.

Osaka E, Yang X, Shen JK, Yang P, Feng Y, Mankin HJ, Hornicek FJ, Duan Z.

J Orthop Res. 2014 Aug;32(8):1075-82. doi: 10.1002/jor.22632. Epub 2014 Apr 24.

33.

Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma.

Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, Nielsen GP, Yang C, Zhang C, Mankin H, Hornicek FJ, Borger DR, Duan Z.

PLoS One. 2014 Apr 2;9(4):e93996. doi: 10.1371/journal.pone.0093996. eCollection 2014.

34.

Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma.

Duan Z, Shen J, Yang X, Yang P, Osaka E, Choy E, Cote G, Harmon D, Zhang Y, Nielsen GP, Spentzos D, Mankin H, Hornicek F.

J Orthop Res. 2014 May;32(5):695-701. doi: 10.1002/jor.22589. Epub 2014 Feb 5.

35.

Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014.

Barranger JA, Brady RO, Grabowski GA, Mankin H, Mistry PK, Weinreb NJ.

Am J Hematol. 2014 May;89(5):457-8. doi: 10.1002/ajh.23687. Epub 2014 Mar 7. No abstract available.

36.

What's new in primary malignant musculoskeletal tumors.

Schwab JH, Springfield DS, Raskin KA, Mankin HJ, Hornicek FJ.

J Bone Joint Surg Am. 2013 Dec 18;95(24):2240-6. doi: 10.2106/JBJS.M.01226. Review. No abstract available.

PMID:
24352776
37.

Development of a new pre-vascularized tissue-engineered construct using pre-differentiated rADSCs, arteriovenous vascular bundle and porous nano-hydroxyapatide-polyamide 66 scaffold.

Yang P, Huang X, Shen J, Wang C, Dang X, Mankin H, Duan Z, Wang K.

BMC Musculoskelet Disord. 2013 Nov 8;14:318. doi: 10.1186/1471-2474-14-318.

38.

Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.

Zhang L, Guo S, Schwab JH, Nielsen GP, Choy E, Ye S, Zhang Z, Mankin H, Hornicek FJ, Duan Z.

PLoS One. 2013 Sep 23;8(9):e75851. doi: 10.1371/journal.pone.0075851. eCollection 2013.

39.

Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells.

Jia B, Choy E, Cote G, Harmon D, Ye S, Kan Q, Mankin H, Hornicek F, Duan Z.

Cancer Lett. 2014 Jan 1;342(1):104-12. doi: 10.1016/j.canlet.2013.08.040. Epub 2013 Sep 2.

40.

Malignant lymphoma of bone: a review of 119 patients.

Demircay E, Hornicek FJ Jr, Mankin HJ, Degroot H 3rd.

Clin Orthop Relat Res. 2013 Aug;471(8):2684-90. doi: 10.1007/s11999-013-2991-x. Epub 2013 Apr 17.

41.

Giant cell tumor of bone.

Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ.

J Am Acad Orthop Surg. 2013 Feb;21(2):118-26. doi: 10.5435/JAAOS-21-02-118. Review.

PMID:
23378375
42.

Pleomorphic spindle cell sarcoma (PSCS) formerly known as malignant fibrous histiocytoma (MFH): a complex malignant soft-tissue tumor.

Mankin HJ, Hornicek FJ, DeLaney TF, Harmon DC, Schiller AL.

Musculoskelet Surg. 2012 Dec;96(3):171-7. doi: 10.1007/s12306-012-0225-0. Epub 2012 Nov 7.

PMID:
23129168
43.

What's new in primary bone tumors.

Schwab JH, Springfield DS, Raskin KA, Mankin HJ, Hornicek FJ.

J Bone Joint Surg Am. 2012 Oct 17;94(20):1913-9. doi: 10.2106/JBJS.L.00955. Review. No abstract available.

PMID:
23079883
44.

Targeting hedgehog-GLI-2 pathway in osteosarcoma.

Yang W, Liu X, Choy E, Mankin H, Hornicek FJ, Duan Z.

J Orthop Res. 2013 Mar;31(3):502-9. doi: 10.1002/jor.22230. Epub 2012 Sep 11.

45.

Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation.

Duan Z, Zhang J, Choy E, Harmon D, Liu X, Nielsen P, Mankin H, Gray NS, Hornicek FJ.

Clin Cancer Res. 2012 Sep 1;18(17):4580-8. doi: 10.1158/1078-0432.CCR-12-1157. Epub 2012 Jul 12.

46.

Establishment and characterization of a novel chordoma cell line: CH22.

Liu X, Nielsen GP, Rosenberg AE, Waterman PR, Yang W, Choy E, Sassi S, Yang S, Harmon DC, Yang C, Schwab JH, Kobayashi E, Mankin HJ, Xavier R, Weissleder R, Duan Z, Hornicek FJ.

J Orthop Res. 2012 Oct;30(10):1666-73. doi: 10.1002/jor.22113. Epub 2012 Apr 13.

47.

Sarcoidosis of the spine: a report of five cases and a review of the literature.

Boyaci B, Hornicek F, Rosenthal D, Mankin H, Pedlow FX Jr, Carrier C, Harms J, Rosenberg A, Schwab J.

J Bone Joint Surg Am. 2012 Apr 4;94(7):e42. doi: 10.2106/JBJS.K.00062. Review. No abstract available.

PMID:
22488626
48.

Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer.

Duan Z, Li X, Huang H, Yuan W, Zheng SL, Liu X, Zhang Z, Choy E, Harmon D, Mankin H, Hornicek F.

J Med Chem. 2012 Apr 12;55(7):3113-21. doi: 10.1021/jm300117u. Epub 2012 Mar 22.

PMID:
22400811
49.

Hand and foot abnormalities associated with genetic diseases.

Mankin HJ, Jupiter J, Trahan CA.

Hand (N Y). 2011 Mar;6(1):18-26. doi: 10.1007/s11552-010-9302-8. Epub 2010 Oct 26.

50.

Osteoid osteoma and osteoblastoma.

Atesok KI, Alman BA, Schemitsch EH, Peyser A, Mankin H.

J Am Acad Orthop Surg. 2011 Nov;19(11):678-89. Review.

PMID:
22052644

Supplemental Content

Loading ...
Support Center